Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 47.8% in March

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 30,500 shares, a drop of 47.8% from the February 29th total of 58,400 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 271,200 shares, the short-interest ratio is currently 0.1 days.

Windtree Therapeutics Price Performance

WINT opened at $0.35 on Friday. The company’s 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.74. Windtree Therapeutics has a 52-week low of $0.28 and a 52-week high of $18.48. The stock has a market capitalization of $1.82 million, a P/E ratio of -0.02 and a beta of 0.60. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.40 and a current ratio of 2.40.

Institutional Investors Weigh In On Windtree Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in shares of Windtree Therapeutics by 54.1% during the 2nd quarter. Renaissance Technologies LLC now owns 361,395 shares of the company’s stock valued at $151,000 after purchasing an additional 126,949 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in Windtree Therapeutics by 97.8% during the fourth quarter. Envestnet Asset Management Inc. now owns 212,236 shares of the company’s stock valued at $36,000 after buying an additional 104,934 shares during the last quarter. Millennium Management LLC raised its position in Windtree Therapeutics by 411.1% in the second quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after acquiring an additional 64,232 shares during the period. Vanguard Group Inc. purchased a new position in shares of Windtree Therapeutics during the 3rd quarter worth $40,000. Finally, Virtu Financial LLC bought a new stake in shares of Windtree Therapeutics during the 4th quarter valued at $28,000. Institutional investors own 29.33% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a report on Wednesday, January 3rd.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.